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Summary
Key molecular lesions in colorectal and other cancers cause -catenin-dependent transactivation of T cell factor (Tcf)-
dependent genes. Disruption of this signal represents an opportunity for rational cancer therapy. To identify compounds
that inhibit association between Tcf4 and -catenin, we screened libraries of natural compounds in a high-throughput assay
for immunoenzymatic detection of the protein-protein interaction. Selected compounds disrupt Tcf/-catenin complexes in
several independent in vitro assays and potently antagonize cellular effects of -catenin-dependent activities, including
reporter gene activation, c-myc or cyclin D1 expression, cell proliferation, and duplication of the Xenopus embryonic dorsal
axis. These compounds thus meet predicted criteria for disrupting Tcf/-catenin complexes and define a general standard
to establish mechanism-based activity of small molecule inhibitors of this pathogenic protein-protein interaction.
Introduction invariably disrupted in colorectal tumors and commonly affected
by mutation in other cancers (de La Coste et al., 1998; Korinek
Each year nearly 150,000 patients are diagnosed with colorectal et al., 1997; Morin et al., 1997; Rubinfeld et al., 1997; Satoh et
cancer in the United States alone, and over 55,000 Americans al., 2000). The net result of these disruptions is stabilization of
-catenin, a multifunctional protein whose principal importancedie of this disease (http://seer.cancer.gov). Besides surgical re-
section, which is rarely curative in advanced disease, current in cancers lies in its ability to bind Tcf/LEF family transcription
factors to activate gene expression (van Noort and Clevers,therapy for colon cancer relies on traditional cytotoxic agents
with limited effects. These considerations make it important to 2002). Gene targets of -catenin-regulated transcription (CRT)
include c-Myc and cyclin D1 (He et al., 1998; Shtutman et al.,develop new treatments based on the appreciation of patho-
genic molecular lesions. Mutations that drive colorectal cancer 1999; Tetsu and McCormick, 1999; van de Wetering et al., 2002),
which have plausible or demonstrated roles in malignancy. Be-are among the best characterized of any human tumor (Kinzler
and Vogelstein, 1996; Markowitz et al., 2002) and present oppor- cause colon cancer most frequently results from loss-of-func-
tion mutations in the APC gene (Kinzler and Vogelstein, 1996;tunities to fashion treatments based on biochemical mecha-
nism. When a similar approach has been applied toward chronic Sparks et al., 1998), which operates as a negative regulator
immediately upstream of -catenin, few signaling componentsmyelogenous leukemia, a disease for which the defining molec-
ular lesion is known, drug development has had a significant afford opportunities for pharmacologic intervention. Within this
restricted field of candidates, the interaction between -cateninimpact on patient outcomes (Druker et al., 2001).
The signaling pathway regulated by Wnt ligands, the adeno- and Tcf/LEF factors represents a rational and feasible target for
drug development. Tcf4 is the factor most prominently ex-matous polyposis coli (APC)-axin complex, and -catenin is
S I G N I F I C A N C E
Colorectal cancer is a major cause of death in the West. Despite significant advances in appreciation of the underlying molecular
mechanisms, current treatments consist exclusively of surgery and conventional chemotherapy, which confer limited benefit. As a
basis for future drug development, we sought to target an early event in tumorigenesis, the critical protein-protein interaction between
-catenin and Tcf transcription factors. We have identified a group of small molecules that disrupt the Tcf/-catenin association, an
activity that we confirmed in a series of independent assays. The isolated compounds provide valuable reagents for drug development
and for detailed investigation of -catenin-dependent cellular pathways. Our approach also highlights the feasibility of targeting
protein-protein interactions in cancer drug discovery.
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pressed in colorectal cancers (Korinek et al., 1997) and also
required for gut crypt stem cell differentiation (Korinek et al.,
1998). Tcf4/-catenin complexes determine cellular responses
in part by controlling expression of c-Myc and p21CIP1/WAF1 (van
de Wetering et al., 2002) and signaling between EphrinB1 and
its receptors EphB2 and EphB3 in the gut epithelium (Batlle et
al., 2002).
Recent studies reveal that tumors rely throughout their natu-
ral history on dysregulation imposed by early molecular lesions
(Chin et al., 1999; Felsher and Bishop, 1999; Fisher et al., 2001),
and interference with CRT can revert transformed phenotypes
in colon cancer. Deletion of the mutant -catenin allele in
HCT116 cells abrogates constitutive CRT and reduces cell
growth and survival (Chan et al., 2002), whereas overexpression
of a dominant inhibitory form of Tcf4 induces G1 cell cycle
arrest in Ls174T and DLD-1 cells, regardless of the presence
of additional (e.g., Trp53) mutations (van de Wetering et al.,
2002). Suppression of CRT did not ostensibly affect DLD-1
cell growth in an independent study but restored epithelial cell
polarity (Naishiro et al., 2001). Thus, although consequences of
dysregulated CRT remain under investigation, disrupting Tcf/
-catenin complexes is likely to convey therapeutic benefit.
Here we report identification of low molecular weight com-
pounds that disrupt Tcf/-catenin complexes. Using indepen-
dent assays, we evaluate the specificity of inhibition and estab-
lish that two compounds function through the predicted
mechanism in vitro and in vivo. The results illustrate an effective
strategy to identify and test drugs directed against protein-
protein interactions, and they outline criteria for compounds to
be regarded as antagonists of distal steps in the Wnt signaling
pathway. Further refinements in drug design can build on these
studies, possibly in conjunction with insights obtained from the
crystal structure of Tcf4/-catenin (Graham et al., 2001; Poy et
al., 2001) and alternative protein complexes.
Figure 1. Antagonists of the Tcf4/-catenin association isolated in a high-
throughput screenResults
A: Schematic illustration of the Tcf4/-catenin ELISA. A -catenin fragment
(residues 134–668) adsorbed to ELISA plates was exposed to GST-Tcf4 (resi-A screen for small-molecule inhibitors
dues 8–54). Bound protein was detected with goat anti-GST antibody, alka-
of the Tcf/-catenin complex line phosphatase (AP)-coupled anti-goat IgG, and AP substrate. Molecules
The interaction between Tcf factors and -catenin requires a that disrupt the Tcf4/-catenin complex yield reduced AP signals.
B: Inhibition of Tcf4/-catenin association, monitored as described in theminimal N-terminal Tcf fragment and the central domain of 12
Experimental Procedures, in the presence of various concentrations of re-armadillo repeats in -catenin (Graham et al., 2000; Molenaar
combinant fusion proteins: SMC1 (yellow triangle), SMC3 (ochre ), HSP70
et al., 1996; Omer et al., 1999). To identify inhibitors of this (violet asterisk), IkB kinase (green square), or -catenin (blue diamond). The
interaction, we developed a binding assay for high-throughput percent inhibition of -catenin binding is expressed as a function of the
concentration of soluble protein used as competitor. Only -catenin be-screening (HTS). Purified -catenin (amino acids 134–668) was
haved competitively in this context.coated on microtiter plates and incubated sequentially with a
Tcf4 fragment (residues 8–54) fused to glutathione-S-trans-
ferase (GST), anti-GST antibody, and alkaline phosphatase (AP)-
conjugated secondary antibody (Figure 1A). Compounds that
solvent for the chemical libraries, did not interfere with the assaydisrupt the Tcf/-catenin complex thus register reduced AP
(data not shown). Antagonism of Tcf4 binding by representativevalues relative to the background.
groups of chemicals showed a normal distribution, with 13%In surface plasmon resonance studies, -catenin binding
standard deviation (SD). These results support our use of awas significantly greater in the presence of tethered GST-Tcf4
nonhomogeneous, microplate-based binding assay to screencompared with unrelated GST-fusion proteins (data not shown).
chemical libraries; we chose inhibition 3 SD of mean bindingFour irrelevant proteins (histidine-tagged SMC1, SMC3 or I-B
as the criterion for activity.kinase, and Hsp70) did not affect Tcf4/-catenin interaction
We screened approximately 7000 purified natural com-at concentrations exceeding 100 g/ml, whereas soluble
pounds from proprietary and public collections, initially at 10-catenin showed dose-dependent inhibition with IC50 (concen-
M concentrations. Eight compounds displayed reproducible,tration giving 50% of the maximal inhibition) 1 g/ml or 19
dose-dependent inhibition of the Tcf4/-catenin interaction withnM (Figure 1B and data not shown), in agreement with previous
estimates (Fasolini et al., 2003). Dimethyl sulfoxide (DMSO), the IC50  10 M, and their structures and purity were confirmed by
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Figure 2. Chemical structures of inhibitors of the
Tcf4/-catenin interaction
The activity of six compounds in the ELISA, mea-
sured in confirmatory assays following the HTS,
is expressed as the concentration (M) of com-
pound required to inhibit the Tcf4/-catenin
association by 50% (IC50). Structures of two
compounds that we did not characterize ex-
tensively and of two compounds used in speci-
ficity studies are shown in Supplemental Figure
S1 at http://www.cancercell.org/cgi/content/
full/5/1/91/DC1.
high-performance liquid chromatography and high-resolution tion of the compounds and/or the Tcf/-catenin complex with
other proteins in the cell extracts or differences in target suscep-mass spectrometry (Figure 2 and Supplemental Figure S1 at
http://www.cancercell.org/cgi/content/full/5/1/91/DC1). tibility between endogenous -catenin and the shorter fragment
used in the HTS. We also examined the effects of three potentThis group of compounds shows diverse structural properties,
although several of them share polyhydroxylated planar fea- compounds on two other protein interactions, CyclinA-E2F1
(Shirodkar et al., 1992) and Bcl-xL/Bax (Yang et al., 1995). Ab-tures; the stereochemistry, where shown, is taken from pub-
lished studies (Takeda et al., 1988). Six compounds are of micro- sence of inhibition of either complex (Figure 3B and data not
shown), other than a trivial decrease in CyclinA precipitation atbial origin: PKF115-584, CGP049090, and PKF222-815 were
isolated from fungal organisms, whereas PKF118-744, PKF118- the highest concentration of PKF115-584, suggests that these
chemicals do not disrupt protein interactions indiscriminately.310, and ZTM000990 originated in Actinomycete strains.
NPDDG39.024 was isolated from the marine sponge Fascaplysi- We used electrophoretic mobility shift assays (EMSA) in
nopsis reticulata (Jimenez et al., 1991), and NPDDG1.024 de- independent biochemical tests of five compounds. EMSA poses
rives from National Cancer Institute collections (NSC#618650- a challenge in colorectal cancer cells, where the abundance of
F/1) without a listed source organism. We identified no additional Tcf factors and -catenin restricts resolution of individual DNA-
active molecules among 45,000 synthetic compounds from No- protein complexes (Korinek et al., 1997; Morin et al., 1997).
vartis archival collections. Although we could detect dose-dependent effects of small mol-
Individual compounds isolated in a single HTS are likely to ecules despite this limitation, protein targets were revealed more
vary in tests of function and no single test may provide definitive clearly in transfected epithelial cells. Nuclear extracts from
evidence of specific biological effects. We evaluated the activi- COS-7 cells transfected with Tcf4 and Flag epitope-tagged
ties of six candidate compounds (Figure 2) in antagonizing -catenin retarded gel migration of a Tcf-consensus DNA probe,
-catenin-dependent processes using a range of independent as expected, and four compounds completely blocked appear-
assays. ance of the Tcf4/-catenin complex bound to DNA (Figure 3C).
PKF118-744 and PKF118-310 did so selectively, whereas
PKF222-815 and PKF115-584 interfered with the faster migrat-Independent confirmation of disrupted
Tcf/-catenin complexes ing complex between Tcf4 and DNA. The latter effect is indepen-
dent of -catenin, as it occurred when cells were transfectedWe incubated protein extracts from HCT116 colon cancer cells
with compounds identified in the HTS and used a GST-Tcf4 only with Tcf4 or with a Tcf4 construct deleted for 53 N-terminal
residues (data not shown). Whereas the results with PKF222-fusion protein to isolate -catenin by affinity chromatography
(Figure 3A). Three compounds (PKF115-584, CGP049090, and 815 and PKF115-584 are hence less informative with respect
to higher-order Tcf complexes, they may suggest that thesePKF222-815) eliminated binding and two others (PKF118-310
and NPDDG39.024) interfered measurably with -catenin pre- compounds interact with Tcf4. Inhibition of -catenin:Tcf4:DNA
complexes by CGP049090, which is active in other biochemicalcipitation. Active compounds showed dose-dependent inhibi-
tion, with IC50 between 10 M and 30 M (Figure 3B). These tests (Figure 3A), was consistent but incomplete.
None of the active agents blocked additional complexesdata confirm the HTS results and reveal subtle differences in
the efficiencies with which individual compounds score in the detected on the Tcf-consensus probe (Figure 3C), implying a
degree of specificity in their action. To extend this specificity,two biochemical assays. These differences may reflect interac-
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we studied effects of the five compounds on other interactions.
Association of pRb-E2F (Figure 3D) and PPAR-RXR (data not
shown) complexes with their cognate DNAs was unaffected.
Compounds identified in the HTS thus disrupt formation of Tcf/
-catenin complexes with demonstrable specificity.
Inhibition of biological markers of Tcf4/-catenin
transactivation
To investigate biologic activity of these compounds, we per-
formed CRT reporter gene assays in HCT116 cells. Because
cytotoxicity was evident over 72 hr of compound treatment
(see below), we measured reporter gene activation at 24 hr.
Moreover, we interpreted CRT results strictly in relation to the
activity of a Tcf-independent -galactosidase reporter, which
served as an internal control for both DNA transfection efficiency
and cell viability and was not impaired by any test compound.
As expected, transient transfection of a firefly luciferase reporter
regulated by three tandem Tcf-consensus binding sites yielded
60-fold induction relative to a control reporter mutated at each
Tcf binding site (data not shown). Compounds isolated in the
HTS inhibited reporter gene activation significantly (Figure 4A),
whereas six independent control compounds, including some
that resemble the test compounds in chemical structure, did
not affect luciferase expression (Figure 4A and data not shown).
Inhibition of the reporter gene by the active compounds was
dose dependent (Figure 4B). These results imply that com-
pounds isolated in the HTS interfere with the targeted signaling
pathway.
To extend these studies on expression of genes known to
be regulated naturally by Tcf4 and -catenin in human cells,
we monitored levels of the CRT-responsive proteins Cyclin D1
and c-Myc (He et al., 1998; Shtutman et al., 1999; Tetsu and
McCormick, 1999; van de Wetering et al., 2002). We treated
HCT116 cells with the compounds and assessed target expres-
sion levels by immunoblot analysis (Figure 4B). PKF115-584
and CGP049090 abrogated expression of both targets, whereas
ZTM000990, PKF118-310, and NPDDG1.024 reduced levels of
either c-Myc or cyclin D1; PKF118-744 did not affect either
target (Figure 4C). No compound affected Cyclin E levels sig-
nificantly, suggesting a selective effect on -catenin targets.
Although HCT116 cells carry the -catenin S45 mutation,
which prevents protein degradation (Liu et al., 2002; Morin et
al., 1997), conceivably the active compounds could activate
some alternative pathway to destroy -catenin. As evidence
Figure 3. Compounds isolated in the HTS inhibit Tcf4/-catenin interaction against this possibility, and consistent with a selective effect,
in independent assays test compounds did not reduce cellular -catenin levels (Fig-
A: Precipitation of cellular -catenin by a GST-tethered Tcf4 fragment. ure 4C).
HCT116 cell extracts were incubated in the absence (	) or presence (100
M) of the indicated compounds and recombinant GST-Tcf4 fusion protein.
Precipitated -catenin levels were assessed by SDS-PAGE and immunoblot-
ting. Many ELISA-active compounds attenuated the Tcf4/-catenin interac-
tion, whereas PKF115-584, CGP049090, and PKF222-815 abrogated binding
totally. radiolabeled Tcf-consensus oligonucleotide (lanes 1–10) or mutated (lane
B: Inhibition of the interaction with GST-Tcf4 is dose dependent. Increasing 11) probes. All samples contained 1% DMSO. Nonspecific DNA-protein asso-
concentrations (10, 30, and 100 M) of the indicated compounds inhibited ciations (NS) are revealed through the pattern seen with the mutated probe
the Tcf4/-catenin interaction with increasing efficiency. Vehicle-treated (lane 11) or in the presence of excess (100) unlabeled probe (lane 3),
sample (	) provides a control and little inhibition was observed for other and a supershifted complex is seen with inclusion of anti-Flag antibody in
protein-protein interactions tested under identical conditions, including that the reaction (lane 4). This latter signal defines the Tcf4/-catenin complex
between Cyclin A and the E2F1 transcription factor. indicated by an arrow to the left and * to the right.
C: Electrophoretic mobility shift assay (EMSA) with COS-7 cell extracts ex- D: Control EMSA with COS cell extracts expressing HA epitope-tagged reti-
pressing full-length Tcf4 and Flag epitope-tagged -catenin. 2.5 g of nu- noblastoma protein pRb, showing binding to a radiolabeled probe specific
clear extract expressing Tcf4, alone (lane 1) or mixed with 1.5 g of nuclear for E2F-family proteins, which are expressed endogenously. Experimental
extract expressing exogenous -catenin (lanes 2–10), were incubated with conditions and labeling of lanes and complexes is as indicated in B.
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Figure 4. Specific inhibition of molecular corre-
lates of CRT
A and B: Inhibition of-catenin-dependent trans-
activation of a Tcf-dependent luciferase re-
porter gene. HCT116 cells were cotransfected
with plasmid encoding E. coli -galactosidase (a
control for transfection efficiency) and either the
TOP-FLASH or FOP-FLASH reporters. Cells were in-
cubated with different concentrations (0.125–10
M) of the compounds and harvested at 24 hr
to measure luciferase and -galactosidase ac-
tivities. Reporter gene activation is expressed in
terms of relative light units (RLU) detected in TOP-
FLASH- or FOP-FLASH-transfected cells and nor-
malized for -galactosidase activity. Results
represent 
3 independent experiments with
each test compound and are shown in A. Panel
B shows that CRT inhibition was dose dependent.
-galactosidase activity was not reduced by
compound exposure, excluding cytotoxicity as
a trivial explanation for the results.
C: Compounds selectively inhibit the endoge-
nous Tcf/-catenin target genes cyclin D1 and
c-Myc. HCT116 cells were incubated for 24 hr
with the chemical compounds (0.5 or 5 M) and
cyclin D1, c-Myc, cyclin E, and -catenin protein
levels were determined by immunoblotting.
Validation of inhibitor activity in vivo tein. Embryo fluorescence was the same with injection of the
compounds as without (Figure 5C). To establish the specificityEarly in Xenopus development, -catenin accumulates on the
prospective dorsal side (Larabell et al., 1997); accurate forma- of inhibited -catenin activity, we co-injected each compound
with siamois mRNA, a target and immediate downstream ef-tion of a dorsal body axis requires nuclear -catenin and activa-
tion of Tcf/-catenin target genes such as Siamois (Brannon et fector of Wnt signaling in Xenopus (Brannon et al., 1997). Sia-
mois’s ability to induce a secondary dorsal axis was not affectedal., 1997). Introducing -catenin mRNA on the future ventral side
activates the Wnt pathway ectopically and induces a secondary by any of the three compounds (Figures 5D and 5E). The active
compounds thus disrupt axis duplication by interfering withbody axis (Figure 5B, compare -catenin-injected tadpoles with
untreated siblings). This developmental pathway thus provides -catenin at a step proximal to Siamois activation and achieve
their effects with minimal developmental toxicity.a rigorous means to test biologic effects of compounds that
might target Tcf/-catenin compexes.
200 pg of ventrally expressed -catenin mRNA induced dor- Tests for antiproliferative and Tcf-specific activities
sal axis duplication in 80% of embryos (Figure 5A). PKF222- Our results highlight the likely specific activity of two or three
815 and PKF118-744 had little or no effect, respectively, on this compounds in disrupting Tcf/-catenin complexes to predict-
result (data not shown), even at doses that caused excessive able biologic effect. To profile cytotoxicity of the eight com-
embryo death. In contrast, co-injection of -catenin mRNA with pounds isolated in our HTS, we assessed their effects on prolif-
0.5 pmol PKF118-310, 3.5 pmol PKF115-584, or 0.25 pmol eration of HCT116 (mutant -catenin, wild-type APC) and HT29
CGP049090 abrogated axis duplication almost completely, with (wild-type -catenin, mutant APC) colon cancer cells (Ilyas et
no contribution from the vehicle, DMSO (Figure 5A). Except for al., 1997; Sparks et al., 1998). Six compounds inhibited cell
a modest increase in embryo death rates with CGP049090, proliferation with IC50 0.2–2 M in both cell lines; PKF222-815
toxic effects at these doses were not significant (Figure 5A), and NPDDG39.024 were less potent (Table 1). Compared to
and each compound restored normal tadpole development in only 1.3% of the natural compounds from this collection that
induce apoptosis in HCT116 cells in vitro (Lee et al., 2003), themost embryos (Figure 5B). The three compounds also failed to
alter normal development through tadpole stages in the absence finding that so many compounds in this small group are cyto-
toxic is highly significant. Six other compounds derived from theof ectopic-catenin (data not shown), which in part likely reflects
limited cytoplasmic diffusion of injected molecules (Drummond same sources (e.g., ZTM002377 and CGP039329, structures
shown in Supplemental Figure S1 at http://www.cancercell.org/et al., 1985).
To exclude an effect resulting from interference with transla- content/full/5/1/91/DC1) did not inhibit growth of either cell line.
If the active compounds interfere with Tcf/-catenin com-tion of injected transcripts, we introduced each active com-
pound together with mRNA encoding the green fluorescent pro- plexes in cells, they may be expected to show greater cytotoxic-
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Figure 5. Compounds inhibit -catenin-induced axis duplication in Xenopus embryos
A: 200 pg -catenin mRNA was injected with selected compounds, vehicle (DMSO), or alone, into the equatorial region of one ventral blastomere of 4-cell
stage Xenopus embryos, and duplicated axes were scored at Nieuwkoop-Faber stage 39. Injection of -catenin mRNA induces an ectopic body axis,
which was blocked by co-injection of PKF118-310 (0.5 pmol/embryo), PKF115-584 (3.5 pmol/embryo), or CGP049090 (0.25 pmol/embryo). The histogram
shows the percent of embryos with normal (gray bars) or duplicated (black bars) axes; injection of DMSO (up to 7% in the injection solution) had no effect
on axis duplication. Results are pooled from several independent experiments, which gave consistent results, and total numbers of scored embryos (n )
are indicated, as is the fraction of embryos that failed to survive to stage 39.
B: Pictures of representative embryos from each pool injected with -catenin mRNA.
C: mRNA encoding the green fluorescent protein (GFP) was injected in the same manner, with or without drugs, and 8–14 embryos, representing all the
samples in a given experiment, were photographed under UV light 30 hr later.
D: 100 pg of Siamois mRNA was injected, with or without candidate compounds, as above, and induction of ectopic dorsal axes was not inhibited by co-
injection of PKF118-310, PKF115-584, or CGP049090. The percent of embryos with normal (gray bars) or duplicated (black bars) axes is depicted.
E: Pictures of representative embryos from each pool injected with Siamois mRNA.
ity toward carcinomas of the colon than those originating in shown). We therefore tested their activity against HCT116 sub-
clones carrying deletion of either the wild-type or mutantother sites. Although excessive -catenin signaling is suspected
to contribute to tumorigenesis in tissues other than the intestine -catenin allele (Chan et al., 2002); growth defects in clones
lacking constitutive CRT are seen only at low cell densities,(Chesire et al., 2002; Lin et al., 2000; Mulholland et al., 2002),
we compared the activity of six compounds toward HCT116 which implies a limited role for -catenin in cell replication, at
least as measured in conventional assays. Parental HCT116cells with that against PC-3 and DU-145 prostate cancer cells.
Cytotoxicity from three compounds was nonselective, whereas cells and the KO58 derivative bearing the constitutively active
-catenin allele responded similarly to treatment with PKF115-PKF222-815, PKF115-584, and CGP049090 showed 3- to
8-fold lower IC50 for colon cancer cells (Table 1). The latter 584, whereas DO20 cells with a wild-type -catenin allele ap-
peared more sensitive (Figure 6A). All three clones showed simi-two molecules also showed 2-fold higher IC100 toward both
prostate-derived lines than against HCT116 cells (data not lar responses to CGP049090 and compound-induced apoptosis
96 CANCER CELL : JANUARY 2004
A R T I C L E
Table 1. Compound effects on growth of colon and prostate cancer cell lines
IC50 in MTS assay
IC100 in MTS assay IC50 ratio
Compound HCT116 HCT116 HT29 PC-3 DU-145 PC3:HCT116
ZTM000990 0.15 0.15 0.15  0.01 0.26  0.06 0.20  0.05 1
PKF118-310 0.35  0.12 0.24  0.09 0.22  0.05 0.30  0.11 0.17  0.01 1
PKF118-744 0.78  0.44 0.65  0.28 0.50  0.10 1.20  0.50 0.42  0.14 1.8
PKF115-584 2.86  0.98 0.40  0.05 2.00  0.16 3.40  0.80 2.88  1.60 8.5
CGP049090 1.20  0.16 0.64  0.20 0.80  0.20 1.70  0.20 0.92  0.13 2.6
NPDDG1.024 NT 0.70 0.60 NT NT
PKF222-815 3.60  0.60 1.20  0.50 NT 7.10  1.40 3.16  0.80 5.9
NPDDG39.024 NT 1.20  0.10 4.20 NT NT
ZTM002377 NT 10 9 NT NT
CGP039329 NT 30 30 NT NT
MTS proliferation assays were performed on two colon (HCT116 and HT29) and two prostate (PC-3 and DU-145) cancer cell lines 72 hr after adding
compounds. Results were obtained in triplicate in each of 5 experiments and are expressed as the average compound concentration (SD) that gives
50% of the maximum inhibition (IC50) or the concentration that returns A490 to the level present at t  0, before addition of compounds (IC100). NT, not tested
with both compounds, as judged by nuclear condensation (DAPI rupt the typically large and hydrophobic interface between inter-
acting proteins (Cochran, 2001; Toogood, 2002). However, criti-staining not shown).
-catenin is essential for many cellular processes. Associa- cal cellular functions rely on protein associations, and neglecting
this reality in drug discovery is needlessly limiting. Drugs withtions with membrane bound E-cadherin and with APC mediate
homotypic cell adhesion and -catenin stability, respectively, established value in treating cancer or other diseases are known
to target essential protein-protein interactions, including thethrough domains that overlap with Tcf binding armadillo repeats
(Graham et al., 2000; Huber and Weis, 2001); this overlap pre- vinca alkaloid inhibitors of tubulin dimerization (Owellen et al.,
1976). Recent studies show that other protein-protein interac-sents a potential obstacle in developing selective drugs (Huber
and Weis, 2001). To evaluate specificity of the active chemicals, tions are also vulnerable to small-molecule interference (Berg
et al., 2002; Chen et al., 2002) and define allosteric interactionswe determined their effect on the presence of E-cadherin and
APC in -catenin immunoprecipitates from HCT116 and HT29 between drug candidates and their target proteins (Arkin et al.,
2003; Baba et al., 1999). Protein associations commonly relycolon cancer cells, respectively. Although three compounds
(PKF222-815, PKF115-584, and CGP049090) reduced the effi- on a few key residues and the Tcf/-catenin complex is no
exception, as revealed by crystal structure and in the deleteriousciency of -catenin immunoprecipitation (see lower relative in-
tensities of both the immunoglobulin and -catenin bands in consequences of single point mutations (Fasolini et al., 2003;
Graham et al., 2000, 2001; Knapp et al., 2001; Omer et al.,Figure 6B), the E-cadherin:-catenin ratio remained constant
(Figure 6C), whereas these compounds eliminated the interac- 1999; Poy et al., 2001). Small molecule antagonists hence need
to interfere mainly with critical amino acid contacts, and modesttion with APC. These results highlight the challenge in selective
antagonism of Tcf/-catenin complexes and suggest that ratio- disruption of the binding equilibrium could have significant out-
comes.nal drug design may need to exploit the known subtle differ-
ences between -catenin’s interactions with Tcf and with pro- We therefore sought to identify natural products that disrupt
interactions between Tcfs and -catenin. To confirm that iso-teins like APC (Eklof Spink et al., 2001).
lated compounds function as predicted, we tested their ability to
inhibit CRT in vitro and in vivo. As expected, six lead compoundsDiscussion
function differently in various secondary assays, albeit with a
correlation between their activities in tests of protein interaction,Molecular pathways of tumorigenesis present opportunities for
cell proliferation, and CRT (Table 2). Two fungal derivativestargeted therapy. This is illustrated well by the utility of Abl
(PKF115-854 and CGP049090) fulfill nearly every tested predic-kinase or epidermal growth factor receptor antagonists in treat-
tion, including disruption of Tcf/-catenin complexes in vitro anding chronic myeloid leukemia and breast cancer, respectively
inhibition of colon cancer cell proliferation, CRT, and -catenin-(Druker et al., 2001; Pegram et al., 1998). The mutations impli-
mediated axis duplication in Xenopus embryos. These com-cated in colon cancer pathogenesis (Kinzler and Vogelstein,
pounds are close analogs of each other and their effects may1996) confer constitutive CRT and high nuclear -catenin levels
occur through the common core structure. This structure does,(Anderson et al., 2002; Korinek et al., 1997; Morin et al., 1997).
Previous attempts to exploit these properties through gene tar- however, raise the possibility of their aggregating in solution,
which can generate false positive results in chemical screensgeting or antisense strategies (Green et al., 2001; Kwong et al.,
2002) validate the seminal role of -catenin in colon cancer, but (McGovern et al., 2002). By nuclear magnetic resonance im-
aging, these molecules did not self-aggregate in several aque-their promise is limited by fundamental barriers to gene-based
treatments. Small molecules that target individual components ous buffers but did so in solutions containing 0.1% Nonidet-
P40 detergent (data not shown). While this may account in partdistally in the APC pathway could bypass these limitations, and
-catenin’s interaction with Tcf4 represents one such target. for the effects we observed in affinity chromatography studies
(Figure 3), molecular aggregates cannot be implicated in ourSmall molecules are commonly considered ill-suited to dis-
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results with nonaggregating buffers in embryos, cells, and nu-
clear extracts. Moreover, these compounds passed rigorous
tests for biochemical specificity, and the weight of evidence
points to effects occurring through the targeted mechanism of
-catenin-protein interactions.
The molecular mechanisms by which the isolated com-
pounds interfere with the targeted interaction are unclear. In
the future, it will be important to map their docking sites within
-catenin and/or Tcf, a goal in which we have met with limited
success to date. Meanwhile, the observation that three com-
pounds also interfere with APC/-catenin complexes suggests
that their actions are mediated through -catenin. Two com-
pounds that disrupt the Tcf4/-catenin complex (PKF115-584
and PKF222-815) also prevent association of Tcf proteins with
DNA. Possibly, these compounds interact additionally with DNA,
as occurs with many small molecules, or modulate Tcf4 allosteri-
cally and less specifically. PKF115-584, whose structure corre-
sponds to that of calphostin C, is known to inhibit protein kinase
C (Kobayashi et al., 1989), but the role of PKC in colon cancer
is unclear. Expression of the  isoform is reduced in colon
cancer cells, hinting at the possibility of a tumor suppressor
function (Assert et al., 1999), whereas PKCII expression in-
creases early in experimental colon tumors in rodents and
PKCII transgenic mice show colonic epithelial hyperprolifera-
tion (Gokmen-Polar et al., 2001; Murray et al., 1999). PKC also
inhibits GSK3- (Cook et al., 1996), the enzyme that targets
-catenin for degradation (Rubinfeld et al., 1996; Yost et al.,
1996). Indeed, calphostin C promotes GSK3- effects and im-
pairs Wnt-induced accumulation of-catenin (Chen et al., 2000),
although other PKC antagonists exert opposite effects (Orford
et al., 1997). Whereas inhibition of PKC could potentially contrib-
ute to PKF115-584 activity, our biochemical and Xenopus data
clearly point to independent effects on Tcf/-catenin com-
plexes; a combination of the two properties may explain the
high potency of this compound in some assays. Conversely,
our results offer an alternative interpretation to the previous
finding of calphostin effects on Wnt signaling (Chen et al., 2000),
which may have resulted from disrupted Tcf/-catenin com-
plexes. Various inhibitors of the -catenin pathway could thus
be useful in studying CRT in normal cellular processes, including
cell growth and replication.
Differences in cell growth between HCT116 cells bearing
deletions of different -catenin alleles are apparent only at low
cell densities (Chan et al., 2002), and alternative means of sup-
pressing CRT affect growth of the DLD-1 cell line differently
(Naishiro et al., 2001; van de Wetering et al., 2002). Conventional
Figure 6. Activity of compounds against colon cancer cells and other cytotoxicity assessments may hence provide limited perspec-
-catenin interactions
tive on the potential roles of new cancer treatments. The cyto-
A: Concentration curves for cytotoxicity (MTS) of PKF115-584 (left) and
toxicity of compounds isolated in our HTS correlates with theCGP049090 (right) toward parental HCT116 colon cancer cells and its inde-
degree to which they attenuate CRT, and the most promisingpendent hemizygous derivatives DO20 (which retains the wild-type
-catenin allele) and KO58 (which retains the mutant -catenin allele). A490 candidates kill colon cancer cells more efficiently than prostate
measurements at 72 hr are reported relative to vehicle (DMSO)-treated cancer cells in vitro. By contrast, they show little difference in
cells. cytotoxicity toward HCT116 derivatives with single -catenin
B and C: Compound effects on -catenin’s interaction with proteins other
alleles. Thus, whereas effects on protein complexes, endoge-than Tcf4. Compounds were added to whole-cell lysates of HCT116 or HT29
nous CRT targets, and embryogenesis seem to occur throughcells to detect E-cadherin or APC, respectively, by immunoblotting of
-catenin immunoprecipitates (i.p.) or the remaining supernatant (s). i  -catenin, cell death may have another basis. The viability of
1/10 of the input cell lysate. Three compounds consistently reduced effi- -catenin S45-deleted HCT116 cells is itself surprising and
ciency of -catenin immunoprecipitation, as judged by the corresponding
may reflect CRT-independent cell growth that resists -catenindecrease in abundance of immunoglobulin heavy (IgH) chain. When the
interference. Alternatively, our compounds may show more pro-results are normalized for this effect (C), they indicate that E-cadherin com-
plexes are preserved, whereas these compounds interfere with the APC/ nounced or specific effects in sensitizing CRT-positive cells to
-catenin interaction. cytotoxic agents.
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Table 2. Summary of biochemical and biologic activities of five compounds studied extensively
Compound ELISA GST EMSA MTS RGA c-Myc Cyclin D1 Axis
PKF115-584   ?     
PKF118-310      -  
CGP049090        
PKF118-744  -    - - -
PKF222-815   ?   NT NT 
Abbreviations: ELISA, enzyme-linked immunosorbent assay; GST, precipitation by glutiathone-S-transferase-tethered Tcf4; EMSA, electrophoretic mobility
shift assay; MTS, cell proliferation assay with 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium; RGA, luciferase reporter
gene activation.
Activities are rated relative to other tested compounds (NT, not tested) according to the following scheme for  and  ratings, respectively: IC50  3 M
or 
 3 M in the ELISA, IC50  1 M or 
 1 M in one or both cell lines in the cell proliferation (MTS) and reporter gene (RGA) assays, inhibition achieved
with 0.5 M compound or only at the 5 M concentration for the endogenous CRT targets c-Myc and cyclin D1, and 80% or 50%–80% inhibition of axis
duplication in Xenopus embryos.
plates were incubated sequentially with goat anti-GST antibody (Amersham-catenin interacts with several proteins, including E-cadh-
Biosciences) for 2 hr and alkaline phosphatase (AP)-conjugated anti-goaterin, APC, and -catenin, so that antagonists of the Tcf interac-
IgG (Bio-Rad) overnight at 4C with 8 washes in TBST in between andtion should be chosen to avoid disrupting its other essential
afterward. Samples were treated for 5 min with 600 g/ml fluorescent AP
functions. CGP049090 and PKF 115-584 antagonize -catenin substrate Attophos (JBL Scientific) in 11 mM MgCl2 (pH 8.8), 4.8 mM dieth-
effects in vivo with limited toxicity, as Xenopus embryos develop anolamine, and enzyme activity was assessed in a fluorescent plate reader
into grossly normal swimming tadpoles, although this observa- (450 nm excitation, 580 nm emission). Compound effects are expressed
as the concentration required to inhibit 50% (IC50) of GST-Tcf4 binding totion likely reflects restricted diffusion of injected molecules
-catenin-coated wells.(Drummond et al., 1985). Indeed, these compounds also disrupt
cellular -catenin/APC complexes, supporting the speculation
Plasmids and cell linesthat pharmacologic interference with -catenin complexes may
hTcf4 and -catenin expression constructs, TOP-FLASH and FOP-FLASH
be inherently unselective (Eklof Spink et al., 2001; Graham et reporters, and the-galactosidase control plasmid used in luciferase reporter
al., 2000). However, crystallographic studies do reveal structural gene assays were purchased from Upstate Biotechnology (Lake Placid, NY).
differences among alternative -catenin complexes (Eklof Spink Flag epitope-tagged -catenin cDNA in the Xenopus expression vector pCS
was kindly provided by Dr. Xi He (Children’s Hospital, Boston, MA), andet al., 2001; Graham et al., 2000), and it may yet be possible
GFP cDNA was subcloned in the same vector. The Tcf4 expression constructto identify antagonists specific for Tcf interactions. Our study
used in gel retardation assays contains the open reading frame of mTcf4Bdemonstrates that some small molecules can disrupt these
(Lee et al., 1999) cloned into the pCMV vector (Stratagene). HCT-116, HT-
complexes with biologic effects. Additional, focused screens 29, and SW480 human colon cancer cells were obtained from the American
and structural refinement could build on these results to develop Type Culture Collection (ATCC) and maintained in McCoy’s, RPMI 1640, or
new treatments for colorectal and other cancers with constitu- Dulbecco’s Modified Eagle medium (Life Technologies), respectively, each
supplemented with 10% fetal bovine serum (FBS). PC-3 and DU-145 pros-tive CRT.
tate cancer cells (ATCC) were cultured in RPMI 1640 medium supplemented
with 10% FBS. HCT116-derived DO20 and KO58 cell lines were generouslyExperimental procedures
provided by Drs. Ken Kinzler and Bert Vogelstein (Johns Hopkins University).
Protein purification and surface plasmon resonance
Precipitation of cellular proteins and immunoblot analysisGST-Tcf4 and untagged human -catenin were prepared as described pre-
GST-Tcf4, GST-E2F1(1-171), and GST-Bcl-xL(135-775) fusion proteins wereviously (Poy et al., 2001) to estimated purities90%. For specificity studies,
purified from E. coli BL21 lysates by affinity chromatography with glutathi-6XHis-SMC1, 6XHis-SMC3, 6XHis-IB kinase, and untagged Hsc70 were
one-sepharose followed either by cation-exchange chromatography or dial-purified from baculovirus-infected Sf9 cells and diluted in Dulbecco’s PBS
ysis in PBS. HCT116 lysates (125 g protein in buffer A containing 50 mM(GIBCO-BRL). CM-5 sensor chips (Biacore Inc., Piscataway, NJ) were coated
Tris [pH 8.0], 250 mM NaCl, 0.1% NP-40, 5 mM EDTA, 10% glycerol, 0.1with goat anti-GST antibody (Amersham Biosciences) using the Biacore BR-
mM sodium vanadate, 1 mM aprotinin, 1 mM leupeptin, 50 mM NaF, 1 mM1002-23a kit for GST fusion protein capture. Following injection of either
phenylmethyl sulfonyl fluoride) were incubated with various concentrationscontrol or GST-Tcf4 (5 l at 20 g/ml) onto separate quadrants of the sensor
of compounds and 5 g GST-fusion proteins overnight at 4C. Sampleschip, -catenin (5 l at 160 g/ml) was introduced to assess specificity of
were immobilized on glutathione-sepharose A beads (Amersham Pharmacia)protein-protein interactions.
for 2 hr at 4C, washed 3 times in buffer B containing 50 mM Tris (pH 8.0),
150 mM NaCl, 0.5% NP-40, and 1 mM EDTA, and the retained material wasCompound libraries and high-throughput ELISA
eluted in SDS-PAGE buffer and resolved in 8% polyacrylamide gels forApproximately 6,000 purified natural products and 45,000 synthetic com-
immunoblot analysis. Cyclin A (H432) and Bax (N20) antibodies (Ab) werepounds originated in Novartis collections, and 1,000 pure natural products
from Santa Cruz Laboratories and -catenin Ab (C19220) was from Trans-were provided through the Natural Product Collaborative Drug Discovery
duction Laboratories. Separately, HCT116 cells were seeded at 106 cells/Group (NPCDDG). Nunc-Immuno MaxiSorp Plates (Nunclon) were coated
plate, cultured overnight at 37C, treated with compounds (0.5–5 M) forwith 5 g/ml purified -catenin fragment in phosphate-buffered saline (PBS);
24 hr, and washed. Cells were lysed in buffer A and 50 g protein wasnonspecific binding was assessed in uncoated wells. Plates were washed
resolved by SDS-PAGE. Relative protein levels were judged by immunoblot8 times with TBST (50 mM Tris [pH 8.0], 0.15 M NaCl, 0.05% Tween-20),
using -catenin, cyclin D1 (SC753, Santa Cruz), c-Myc (Ab1, Oncogeneblocked for 2 hr at 4C with SuperBlock (Pierce), washed with TBST, incu-
Research Products), or cyclin E (SC247, Santa Cruz) Ab and enzymaticbated for 2 hr at 4C with 1 g/ml purified GST-Tcf4 in the presence of 10
chemiluminescence (Amersham Pharmacia). Finally, HT29 and HCT116M compounds diluted in assay buffer (50 mM Tris [pH 8.0], 0.15 M NaCl,
whole-cell extracts prepared in buffer C (140 mM NaCl, 20 mM Tris [pH 8],0.05% Tween-20, 2% bovine serum albumin) with a final concentration of
1% DMSO, followed by 8 washes in TBST. To detect bound GST-Tcf4, 1.5 mM MgCl2, 1 mM EGTA, 1% Triton X-100, 10% glycerol) were precleared
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with protein G beads (Amersham Pharmacia), incubated with DMSO or mRNA was performed similarly and fluorescence was assessed after 36 hr
at stage 25.compounds at 30 M for 4 hr at 4C, and treated with 4 g mouse -catenin
Ab (BD Biosciences) at 4C overnight, followed by 20 l protein G slurry
and 3 washes in buffer C. Precipitates were resolved on Tris-acetate gels Acknowledgments
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